checkAd

    DGAP-News  1055  0 Kommentare EVOTEC AND ETERNYGEN TO DEVELOP NOVEL METABOLIC DISEASE THERAPY

    DGAP-News: Evotec AG / Key word(s): Alliance
    EVOTEC AND ETERNYGEN TO DEVELOP NOVEL METABOLIC DISEASE THERAPY

    09.01.2017 / 07:29
    The issuer is solely responsible for the content of this announcement.

    ---------------------------------------------------------------------------

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Evotec SE!
    Short
    13,75€
    Basispreis
    0,93
    Ask
    × 14,08
    Hebel
    Long
    12,27€
    Basispreis
    0,94
    Ask
    × 13,93
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    * Evotec participate in Eternygen's EUR 8 m (approx. $ 8.3 m) Series A
    funding round together with Epidarex Capital, the lead investor, and a
    consortium of prominent German investors
    * Evotec to provide all pre-clinical drug discovery activities in
    collaboration with Eternygen

    Hamburg, Germany, 09 January 2017:
    Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809)
    announced today that it will extend its existing relationship with
    Eternygen GmbH ("Eternygen") by becoming an investor in addition to being a
    pre-clinical drug discovery partner. Within a consortium of investors
    including VC Fonds Technologie Berlin, managed by IBB
    Beteiligungsgesellschaft mbH, and two renowned family offices, Epidarex and
    Evotec together will participate in Eternygen's latest funding round of EUR
    8 m (approx. $ 8.3 m).

    Eternygen, a privately owned metabolic diseases company based in Berlin,
    Germany, is focused on the sodium coupled citrate transporter ("NaCT"), a
    novel target which is also known as INDY ("I am Not Dead Yet"). INDY is a
    key regulator of energy metabolism that may be involved in the pathogenesis
    of nonalcoholic fatty liver disease ("NAFLD"), nonalcoholic steatohepatitis
    ("NASH"), diabetes and obesity. Eternygen will use the proceeds of the
    Series A funding to accelerate its small molecule NaCT inhibitors towards
    the selection of a pre-clinical lead candidate. Eternygen will rely on
    Evotec's best-in-class drug discovery platform and metabolic disease
    expertise to conduct all work to the selection of pre-clinical development
    candidate and possibly beyond.

    Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are
    very excited to take part in the growth and ownership of a company which
    together with Evotec has assembled world-leading expertise and tools around
    a very promising mechanism in metabolic diseases. Combining academic
    excellence with a highly focused management team and a proven platform is a
    highly effective model for Evotec to bring forward projects with
    first-in-class potential. Eternygen perfectly fits into this mold."

    Marco Janezic, CEO Eternygen GmbH, said: "The successful completion of our
    series A round with a syndicate of renowned investors is great recognition
    Seite 1 von 3


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News EVOTEC AND ETERNYGEN TO DEVELOP NOVEL METABOLIC DISEASE THERAPY DGAP-News: Evotec AG / Key word(s): Alliance EVOTEC AND ETERNYGEN TO DEVELOP NOVEL METABOLIC DISEASE THERAPY 09.01.2017 / 07:29 The issuer is solely responsible for the content of this announcement. …

    Schreibe Deinen Kommentar

    Disclaimer